Variable | No. of patients (%) | Post-treatment hypoalbuminemia group (<36.4 g/L) | Normal post-treatment albumin level group (≥36.4 g/L) | P value |
---|---|---|---|---|
Sex | Â | Â | Â | 0.589 |
 Men | 137 (74.5) | 27 (71.1) | 110 (75.3) |  |
 Women | 47 (25.5) | 11 (28.9) | 36 (24.7) |  |
Age (years) | Â | Â | Â | 0.215 |
 <65 | 141 (76.6) | 32 (84.2) | 109 (74.7) |  |
 ≥65 | 43 (23.4) | 6 (15.8) | 37 (25.3) |  |
Pathologic type | Â | Â | Â | 0.060 |
 ccRCC | 179 (97.3) | 35 (92.1) | 144 (98.6) |  |
 nccRCC | 5 (2.7) | 3 (7.9) | 2 (1.4) |  |
History of nephrectomy | Â | Â | Â | 0.945 |
 Yes | 146 (79.3) | 30 (79.0) | 116 (79.5) |  |
 No | 38 (20.7) | 8 (21.0) | 30 (20.5) |  |
History of cytokine treatment | Â | Â | Â | 0.811 |
 Yes | 66 (35.9) | 13 (34.2) | 53 (36.3) |  |
 No | 118 (64.1) | 25 (65.8) | 93 (63.7) |  |
Fuhrman grade | Â | Â | Â | <0.001 |
 1–2 | 104 (56.5) | 9 (23.7) | 95 (65.1) |  |
 3–4 | 65 (35.3) | 24 (63.2) | 41 (28.1) |  |
 Unknown | 15 (8.2) | 5 (13.1) | 10 (6.8) |  |
Number of metastatic sites | Â | Â | Â | 0.053 |
 1 | 130 (70.7) | 22 (57.9) | 108 (74.0) |  |
 ≥2 | 54 (29.3) | 16 (42.1) | 38 (26.0) |  |
Metastatic site | Â | Â | Â | Â |
 Lung | 137 (74.5) | 33 (86.8) | 104 (71.2) | 0.050 |
 Lymph node | 44 (23.9) | 11 (29.0) | 33 (22.6) | 0.414 |
 Bone | 20 (10.9) | 0 (0.0) | 20 (13.7) | 0.034 |
 Liver | 16 (8.7) | 2 (5.3) | 14 (9.6) | 0.400 |
 Others | 15 (8.2) | 2 (5.3) | 13 (8.9) | 0.465 |
MSKCC risk category | Â | Â | Â | 0.072 |
 Favorable | 83 (45.1) | 12 (31.6) | 71 (48.6) |  |
 Intermediate | 72 (39.1) | 18 (47.4) | 54 (37.0) |  |
 Poor | 29 (15.8) | 8 (21.0) | 21(14.4) |  |
NLR | Â | Â | Â | 0.440 |
 <2.2 | 73 (39.7) | 13 (34.2) | 60 (41.1) |  |
 ≥2.2 | 111 (60.3) | 25 (65.8) | 86 (58.9) |  |
First-line therapy | Â | Â | Â | 0.149 |
 Sorafenib | 112 (60.9) | 27 (71.1) | 85 (58.2) |  |
 Sunitinib | 72 (39.1) | 11 (28.9) | 61 (41.8) |  |